Abstract
The enzyme poly(ADP)-ribose polymerase-1 (PARP-1) plays an important role in the repair of DNA damage via a mechanism called base excision repair (BER). Initially, inhibition of PARP-1 showed to be a promising anti-tumor strategy in preclinical models using BRCA1 and BRCA2 deficient tumor cell lines. More recently, several small molecules targeting PARP-1 entered the clinic and demonstrated compelling anti-tumor activity in patients with BRCA deficient breast and ovarian cancers, and in patients with triple-negative breast cancer. In this review we aim to summarize the most recent advances in the development of PARP inhibitors, with a focus on the clinical data.
Keywords: Synthetic lethality, repair mechanism, PARP, BRCA deficient, olaparib
Current Clinical Pharmacology
Title: Inducing Synthetic Lethality using PARP Inhibitors
Volume: 5 Issue: 3
Author(s): David S. Boss, Jos H. Beijnen and Jan H.M. Schellens
Affiliation:
Keywords: Synthetic lethality, repair mechanism, PARP, BRCA deficient, olaparib
Abstract: The enzyme poly(ADP)-ribose polymerase-1 (PARP-1) plays an important role in the repair of DNA damage via a mechanism called base excision repair (BER). Initially, inhibition of PARP-1 showed to be a promising anti-tumor strategy in preclinical models using BRCA1 and BRCA2 deficient tumor cell lines. More recently, several small molecules targeting PARP-1 entered the clinic and demonstrated compelling anti-tumor activity in patients with BRCA deficient breast and ovarian cancers, and in patients with triple-negative breast cancer. In this review we aim to summarize the most recent advances in the development of PARP inhibitors, with a focus on the clinical data.
Export Options
About this article
Cite this article as:
S. Boss David, H. Beijnen Jos and H.M. Schellens Jan, Inducing Synthetic Lethality using PARP Inhibitors, Current Clinical Pharmacology 2010; 5 (3) . https://dx.doi.org/10.2174/157488410791498798
DOI https://dx.doi.org/10.2174/157488410791498798 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Editorial [Hot Topic:Non-Receptor Tyrosine Kinases as Molecular Targets for Patient Tailored Cancer Therapy (Guest Editors: F.M. Uckun, A. Vassilev and H. Tibbles)]
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Isoxazole Moiety Containing Thieno[2,3-d]pyrimidine Derivatives and Preliminarily in vitro Anticancer Activity (Part II)
Anti-Cancer Agents in Medicinal Chemistry Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer
Current Signal Transduction Therapy Gene Therapy of Cancer Based on Interleukin 12
Current Gene Therapy Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Current Bioactive Compounds Butyrate and Colorectal Cancer: The Role of Butyrate Transport
Current Drug Metabolism Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) Anthrax Fusion Protein Therapy of Cancer
Current Protein & Peptide Science Immune Receptors, Cadherins and their Interactions
Current Immunology Reviews (Discontinued) Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Recent Patents on Anti-Cancer Drug Discovery Walking the Oxidative Stress Tightrope: A Perspective from the Naked Mole-Rat, the Longest-Living Rodent
Current Pharmaceutical Design Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design Breast Cancer Diagnosis Using Data Mining Methods, Cumulative Histogram Features, and Gary Level Co-occurrence Matrix
Current Medical Imaging Therapeutic Uses of HSP90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC)
Current Drug Metabolism Overview on Anticancer Drug Design and Development
Current Medicinal Chemistry Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Rheb/mTOR Activation and Regulation in Cancer: Novel Treatment Strategies beyond Rapamycin
Current Drug Targets Synthesis of Novel Fused Regioisomeric Oxetane Bicycles via Paternò-Büchi Reaction of L-Ascorbic Acid and Evaluation as Antiproliferative Agents
Current Organic Synthesis Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry